Q2 2025 Alligator Bioscience AB Earnings Call Transcript
Key Points
- Alligator Bioscience AB (FRA:7AL0) has advanced its lead asset, mitazalimab, with regulatory endorsements from both the EMA and FDA for its Phase 3 protocol and dose.
- The company has secured GMP material for the Phase 3 study and commercial supply of mitazalimab, ensuring readiness for the next phase of development.
- New biomarker data presented at major conferences supports patient selection strategies and validates the mechanism of action for mitazalimab, enhancing its potential as a first-line treatment for metastatic pancreatic cancer.
- Alligator Bioscience AB (FRA:7AL0) raised SEK61 million, indicating strong shareholder support and financial backing for ongoing projects.
- The company has reduced its burn rate significantly, aligning with its cost reduction program, and expects a burn rate of SEK20 million to SEK25 million per quarter moving forward.
- Despite progress, the company still requires additional activities to be fully Phase 3 ready, including completing stability studies for mitazalimab.
- The financial situation remains challenging, with reliance on the successful subscription of TO 13 warrants to secure funding for the remainder of 2025.
- There is uncertainty around the potential financial outcomes of the HLX22 asset, with conservative estimates differing from partner projections.
- The company faces ongoing risks and uncertainties in securing a partnership or trade sale for mitazalimab, with discussions progressing slower than desired.
- Alligator Bioscience AB (FRA:7AL0) has a limited cash runway, necessitating prudent financial management and exploration of additional financing avenues.
So hello, and welcome to Alligator Biosciences Interim Report Call for the second quarter of 2025. My name is Greta Hoog, I'm the IR and Communications Manager at Alligator and I will be introducing today's call. With me today are our CEO, Soren Bregenholt; and our CFO, Johan Gileus. They will walk you through the latest developments from the quarter and the upcoming news flow, after which they will be happy to answer any questions you may have. Now before we begin, I would like to share a quick reminder that during today's call, management may make forward-looking statements that involve known and unknown risks, uncertainties and other important factors beyond the company's control that could cause the company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements.
These statements are subject to risks and uncertainties that could cause actual results to differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
